Distribution and Clinical Analysis of EpCAM+/Vimentin+ Circulating Tumor Cells in High-Risk Population and Cancer Patients

Chunjin Huang1†, Sheng Ding2†, Chunyan Huang3†, Feng Pan4, Xiaodong Liu4, Haijiao Zhang3, Jian Zhou5, Xiaofei Liang5, Xinyan Wang5 and Ping Song5

1 Department of General Surgery, Huadong Hospital Affiliated to Fudan University, Shanghai, China, 2 Department of Stomatology, Xinhua Hospital Affiliated to Shanghai Jiao tong University School of Medicine, Shanghai, China, 3 Department of Anesthesia, Zhabei Central Hospital of Shanghai, Shanghai, China, 4 Department of Orthopedics, Zhabei Central Hospital of Shanghai, Shanghai, China, 5 Project Department, Huzhou Lieyuan Medical Laboratory Company Ltd, Huzhou, China

Circulating Tumor Cells (CTCs) are already present in the peripheral blood of patients with early tumors and even precancerous lesions. The objective of this study was to determine the count of CTCs in peripheral blood from high-risk population (HRP), healthy subjects and patients with Pan-cancer. The CTCs in the peripheral blood from HRP and cancer patients were enriched and identified based on the positive sorting method by epithelial cell adhesion molecular (EpCAM) liposome magnetic bead (Ep-LMB) and Vimentin liposome magnetic bead (Vi-LMB). Simultaneously, further analysis was carried out focusing on the clinical characteristics of patients by collecting the peripheral blood samples from healthy subjects as the parallel control. According to the results, the prepared LMBs had high specificity and stability, resulting in an average (Av) proliferation rate of over 90% for each cell line, and the average capture rate of higher than 80%. In terms of CTCs count detection in clinical blood samples, the average count was 0.9 (Ep: Av=0.6, Vi: Av=0.3), 2.4 (Ep: Av=1.4, Vi: Av=0.8) and 7.3 (Ep: Av=4.0, Vi: Av=3.3) in healthy subjects, HRP and total cancer patients, respectively. Besides, there was no obvious difference in the average count of CTCs among patients with different cancer types. While count of CTCs in the aforementioned cancer patients was statistically different from that in healthy subjects and patients with HRP. The survival time of cancer patients whose number of CTCs is greater than the average is significantly increased. Collectively, the study confirmed that CTCs can achieve early tumor detection and auxiliary diagnosis, and its number is related to the occurrence and development of tumors, and CTCs can be detected in HRP and sub-health population.

Keywords: cancer, circulating tumor cells, epithelial cell adhesion molecular, vimentin, high-risk population
INTRODUCTION

Circulating tumor cells (CTCs) are cells originating from the primary lesion that abscission to the peripheral blood; they have a putative role in metastasis formation (1, 2). Their presence in patients with solid tumors at all disease stages is well established (3, 4), and they have the same cytomorphic features as the solid tumor (5). Detection of CTCs in the peripheral blood of cancer patients can be prognostic and may have a large impact on the development of new strategies for cancer treatment (6, 7). CTCs have recently emerged as an important potential biomarker of the diagnosis, evaluation of treatment response, and prognosis in cancers including lung cancer (8), gastric cancer (9), colorectal cancer (10), liver cancer (11) and esophageal cancer (12).

Studies have found that the formation of CTCs is related to epithelial mesenchymal transition (EMT). EMT is the process of conversion from an epithelial to a mesenchymal phenotype, resulting in expression of mesenchymal markers (Vimentin) and loss of epithelial markers (epithelial cell adhesion molecular, EpCAM). The recent methods of epithelial cell adhesion molecule (EpCAM)-based CTCs analysis showed limitations to detecting CTCs in patients with tumors (13, 14), because some CTCs express only epithelial or mesenchymal markers (15, 16). The vimentin are highly expressed in a variety of tumor cells, especially in tumor cells with EMT (17). Therefore, vimentin may be a potential target for capturing CTCs in patients with tumor. A novel EpCAM+/Vimentin+ -based CTC analysis method had been developed on the basis of this fact.

An accurate counting of CTCs can be used in the clinical application of auxiliary means for tumor staging (18), curative effect monitoring (19), recurrence prediction (20), prognosis evaluation (21, 22), etc. For instance, a previous study found that >5 CTCs were detected in 7.5 mL blood samples, which generally indicated poor clinical results, i.e., significantly shortened overall survival and progression free survival. It suggested that the count of CTCs can reflect the therapeutic effect and the survival of cancer patients (23, 24). Meanwhile, Algizawy, et al. carried out a study by enrolling 85 breast cancer patients and confirmed that the count of CTCs can be used as an auxiliary means to monitor the progress of the disease (25).

With respect to the above, the present study was conducted focusing on the capture of CTCs in peripheral blood of healthy subjects, patients with high-risk population (HRP) and those with different types of cancer on the basis of the preparation of EpCAM+/Vimentin specific immunomagnetic beads, with the aim to study the difference of CTCs counts of non-cancer patients with healthy subjects and cancer patients.

MATERIALS AND METHODS

Objects of Study
The objects of study were 32 cases of HRP diagnosed in our hospital from 2017 to 2019, HRP is for patients with disease (Including: lumbar disc herniation, coronary heart disease, diabetes, chronic gastritis, appendicitis, acute bronchitis, rheumatoid arthritis etc.), as well as 37 cases of lung cancer, 33 cases of gastric cancer, 38 cases of colorectal cancer, 32 cases of liver cancer, 34 cases of esophageal cancer and 25 cases of healthy volunteers from Huzhou Lieyuan Medical Laboratory Co., Ltd. The method of collecting blood samples is to collect 3.75 mL of peripheral blood of patients with medical anticoagulant blood vessels, and the anticoagulant is EDTA K2. This study was approved by the Ethics Committee of Zhebei Central Hospital of Shanghai (ZBLL20180823). Participants were given written consent after receiving verbal and written information.

Cell Lines
MKN-45 gastric cancer cells, Li-7 liver cancer cells, A549 lung cancer cells, KYSE450 esophageal cancer cells, and SW116 colorectal cancer cells were purchased from Shanghai Cell Bank of Chinese Academy of Sciences. Cells were cultured in RPMIL640 medium containing 10% fetal bovine serum in a 5% CO₂ constant-temperature incubator at 37°C.

Materials and Instruments
DMEM culture medium, fetal bovine serum and trypsin (Gibco); Fe₃O₄ solution, hexadecyl-quaternized (carboxymethyl) chitosans (HQCMC), CK-FITC, CD45-PE and DAPI (Huzhou Lieyuan Medical Laboratory Co., Ltd.); 1,2 dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC), glycidyl hexadecyl dimethylammonium chloride (GHDC), cholesterol, N-hydroxysuccinimide (NHS), and 1-ethyl-3-(3-dimethyl aminopropyl)-carbodiimide (EDC) (Sinopharm); EpCAM antibody and Vimentin antibody (CST); BI-90Plus Nanoparticle Size Analyzer/Zeta potentiometer (Brookhaven, USA); OLYMPUS BX61 fluorescence microscope (Olympus, Japan); and LDJ9600-1 magnetic property measurement system (MPMS) (Digital Instruments Inc., USA).

Preparation of Liposome Immunomagnetic Beads
Three micron-nano-sized liposome immunomagnetic beads in this study were prepared by inverted evaporation. Taking epithelial cell adhesion molecular (EpCAM) liposome magnetic bead (Ep-LMB) as an example, with dichloromethane as a co-solvent, the liposome matrix was prepared using cholesterol, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), glycidyl hexadecyl dimethylammonium chloride (GHDC) and hexadecyl-quaternized (HQCMC). Fe₃O₄ was suspended in 0.1 mol/L PBS solution (pH=7.4), and dropped into the liposome matrix. Using a probe-type ultrasonic instrument, the mixed solution was subject to ultrasonic vibration to realize a complete emulsification, and the liposome magnetic bead (LMB) was obtained. A proper amount of EpCAM antibodies was dissolved in 10mL isopropanol, followed by the addition of coupling N-Hydroxy succinimide (NHS) and 1-ethyl-3-[3(dimethyl aminopropyl) carbodiimide, hydrochloride (EDC). After that, the mixed solution was stirred at 4°C for 24 h at a constant speed to obtain EpCAM antibodies modified LMB, named Ep-LMB. It was added with distilled water and diluted (1mg/mL) for further usage. The preparation of Vimentin liposome magnetic bead (Vi-LMB) followed the same method as that of Ep-LMB.
Characterization Tests
The prepared Vi-LMB and Ep-LMB were tested by MPMS; BI-90Plus Nanoparticle Size Analyzer/Zeta potentiometer were used for the test of particle size and potential of LMB; the ultraviolet absorption spectrum of LMB was scanned by UV spectrophotometer, and its morphology was observed by atomic force microscope (AFM).

Cytotoxicity Test
The cultured cancer cells were digested into suspension and counted with Hemocytometer. The cells were added into 96-well plate, with 1,000 cells per well, and the medium was 200μL. In the cell sampling treatment, the addition amount of Vi-LMB and Ep-LMB was 5μg/mL, 10μg/mL, 20μg/mL, 30μg/mL, 40μg/mL, 50μg/mL and 60μg/mL, respectively. A control group was established with DMSO, with 3 repetitions for each concentration of each LMB. MTT test was started following 72 h of culture of the 96-well plate in CO2 incubator. After incubation in CO2 incubator for 2 h, the cell proliferation rate was calculated by measuring the absorbance of each well at the wavelength of 560nm by using Multiskan Spectrum.

In Vitro Simulation of CTCs Capture Test
The cultured A549 cells were digested into suspension and counted with Hemocytometer, with 100 cells in 3.75mL PBS. In Ep-LMB group, 5, 10, 15, 20 and 25μL1μg/μL Ep-LMB were added separately, while 5, 10, 15, 20 and 25μL1μg/μL Vi-LMB were added respectively in Vi-LMB group. Three repetitions were set for magnetic separation and capture of cells in each group. The capture efficiency was calculated by counting using FITC labeled CK19 monoclonal antibody (CK19-FITC), DAPI staining solution and PE labeled CD45 antibody (CD45-PE) staining. The addition amount with the maximum capture rate was obtained, followed by verification in different cancer cells. Further study was performed on the total capture rate of Ep-LMB combined with Vi-LMB in different cells. Simultaneous verification was carried out in terms of the stability of Ep-LMB and Vi-LMB to different cell lines. Finally, through the patient blood simulation system, the above methods were used to add different tumor cells to verify the separation efficiency.

CTCs Capture and Counting of Clinical Blood Samples
An amount of 3.75mL peripheral blood samples were added to 20μL Vi-LMB for capture, followed by capture with the addition of 20μL Ep-LMB. After capture, magnetic separation was carried out using 10μL FITC labeled CK19 monoclonal antibody (CK19-FITC), 20μL DAPI staining solution and 10μL PE labeled CD45 antibody (CD45-PE) staining in dark for 15 min after well mixing. At the end of staining, magnetic separation was conducted after the LMB was washed with 1mL distilled water. Following magnetic separation, discarding of the solution and repeated washing twice, 20μL solution was mixed with 20μL distilled water in the centrifugal tube, and the mixture was applied uniformly into the polylysine treated anti-off slides. After the droplets dried naturally, the slides were observed and counted under the fluorescence microscope.

Statistical Analysis
SPSS21.0 statistical software was used to analyze the data (mean ± standard deviation) of this study. One-way analysis of variance was used for comparison at different time points, and SNK test was utilized for pairwise comparison. Besides, comparison between groups applied t test. P<0.05 (*P<0.05; **P<0.01; ***P<0.001) meant that the difference was statistically significant.

RESULTS
CTCs Capture and Counting Analysis
The CTCs in the 3.75mL peripheral blood from HRP and cancer patients were enriched and identified based on the positive sorting method by Ep-LMB and Vi-LMB. Simultaneously, further analysis was carried out focusing on the clinical characteristics of patients by collecting the 3.75mL peripheral blood samples from 25 healthy subjects as the parallel control. Clinical blood CTCs and detection process in Figure 1.
Characterization of Liposome Immunomagnetic Beads

Figure 2 shows the characterization results of three magnetic beads prepared. Figures 2A, B described the particle size distribution of Ep-LMB and Vi-LMB, with corresponding average (Av) particle size of 236.6 ± 1.2nm and 240.9 ± 1.5nm, respectively. Figures 2G, H are atomic force test results of Ep-LMB and Vi-LMB. The two magnetic microspheres were observed to be spherical with different sizes and regular shapes without agglomeration. Furthermore, Figures 2C, D display the potential distribution of Ep-LMB and Vi-LMB. Both magnetic microspheres were positively charged that might benefit the dispersed beads in a hydrophilic solution. The ultraviolet scanning results of immunomagnetic beads are shown in Figures 2E. There existed no absorption peak at 280nm for LMB, but absorption peaks at 280nm for both Vi-LMB and Ep-LMB, which had the characteristics of protein ultraviolet absorption. It suggested that EpCAM and vimentin antibodies were indeed grafted to the surface of the magnetosphere. Figure 2F is the hysteresis curve of Vi-LMB and Ep-LMB. The magnetic properties of liposomes coated with antibody were much higher than that of liposome immunomagnetic beads with antibody grafted. Further comparative analysis indicated that Fe3O4 was coated by liposome and then coupled with antibody. Its intensity of magnetism was weakened to some extent in the later stage, suggesting that Fe3O4 was successfully coated by liposome and grafted with antibody.
Cell Cytotoxicity

Figures 3A, B show the results of cell proliferation rate of Ep-LMB and Vi-LMB treated with different concentrations. When the concentration of Ep-LMB and Vi-LMB was below 20μg/mL, their toxicity to cancer cells was relatively small, with the cell proliferation rate of each cell line of >90%. The cell proliferation rate decreased with the increase of the concentration of magnetic beads, indicating that excessive concentration of magnetic beads might have certain toxicity to cells. Furthermore, when the concentration of Ep-LMB and Vi-LMB was 60μg/mL, the proliferation rate of each cell line was still more than 60% and 50%, respectively. It revealed that both Ep-LMB and Vi-LMB might be less toxic despite the presence of cytotoxicity to each cell line.

Capture Efficiency of Vi-LMB and Ep-LMB for Cancer Cells

The results of in vitro simulation of CTCs capture efficiency are shown in Figure 4. Figure 4A shows the capture efficiency of Ep-LMB and Vi-LMB at different usages for A549 cells in PBS system. The capture efficiency peaked when the usage of Ep-LMB and Vi-LMB was 20μL (51% and 49%, respectively), with no obvious change in capture rate with increasing usage. On the basis of obtaining the optimal usage amount of Ep-LMB and Vi-LMB from A549 cells, the next step was to explore whether there was effect in other cell lines. As shown in Figure 4B, there was no obvious difference in the capture efficiency of Ep-LMB and Vi-LMB for MKN-45, Li-7, SW116 and KYSE450 cell lines when compared to that for A549 cells. In order to improve the efficiency of cell capture, Ep-LMB combined with Vi-LMB were used to capture cell lines (Figure 4C). A combined usage of Ep-LMB and Vi-LMB resulted in significant increase of the capture rate, and the capture rate for each cell line was over 80%, showing no statistical difference (P>0.05). According to the results of the stability of the total capture rate for each cell line by the combination of Ep-LMB and Vi-LMB (Figures 4E, F), the combined usage resulted in a relatively stable capture efficiency of each cell (average capture rate of >80%), suggesting the feasibility and stability of this method for CTCs capture in clinical blood samples.

Capture and Identification of CTCs in Clinical Blood Samples

Besides CTCs, cells after magnetic enrichment included a certain number of erythrocyte and leukocyte. At present, the recognition of CTCs was mainly based on the specific expression of CTCs antigen. Thus, CTCs were identified in this experiment by immunofluorescence staining. Under the white light microscope, in the presence of visible cell morphology, strong positive CK19-FITC green fluorescence and DAPI blue fluorescence, and negative CD45 staining, it could be judged that the cell captured by the magnetic bead from the blood was CTCs. Figure 5A shows the results of immunofluorescence assay in blood samples of healthy subjects, as well as patients with HRP and different types of cancer. As shown in this figure, CTCs could be captured in blood samples from healthy subjects, as well as patients with HRP and different types of cancer. Figure 5B is a hotspot map of CTCs count captured by Ep-LMB and Vi-LMB in blood samples of healthy subjects, as well as patients with HRP and different types of cancer. It was observed that the count of CTCs captured by Vi-LMB and Ep-LMB in the blood samples of cancer patients was significantly higher than that of healthy subjects and patients with HRP. Figure 5C shows the distribution of Ep-LMB CTCs in blood samples of healthy subjects, HRP patients and patients with different types of cancer. The Ep-LMB CTCs count in healthy subjects and HRP patients was lower than that in patients with various cancers. Meanwhile, based on Figure 5D, there was no significant difference in the average Ep-LMB CTCs count among patients with various cancers (P>0.05). The count of Ep-LMB CTCs in patients with various cancers was statistically different from that in healthy subjects and patients with HRP (P<0.05). Besides, the count of Ep-LMB CTCs in patients with HRP was significantly higher than that in healthy subjects. The average Ep-LMB CTCs count in each group was described as follows: (Av=0.6,
N=25) in healthy subjects, (Av=1.4, N=32) in HRP patients, (Av=3.9, N=37) in lung cancer patients, (Av=4.1, N=33) in gastric cancer patients, (Av=4.2, N=38) in colorectal cancer patients, (Av=3.8, N=34) in esophageal cancer patients, and (Av=4.0, N=174) total cancer patients. Figure 5E shows the distribution of Vi-LMB CTCs in blood samples of healthy subjects, HRP patients and patients with different types of cancer. The Vi-LMB CTCs count in healthy subjects and HRP patients was lower than that in patients with various cancers. Meanwhile, based on Figure 5F, there was no significant difference in the average Vi-LMB CTCs count among patients with various cancers (P>0.05). The count of Vi-LMB CTCs in patients with various cancers was statistically different from that in healthy subjects and patients with HRP (P<0.01). Besides, the count of Vi-LMB CTCs in patients with HRP was significantly higher than that in healthy subjects. The average Vi-LMB CTCs count in each group was described as follows: (Av=0.3, N=25) in healthy subjects, (Av=0.8, N=32) in HRP patients, (Av=3.5, N=37) in lung cancer patients, (Av=3.1, N=33) in gastric cancer patients, (Av=3.6, N=38) in colorectal cancer patients, (Av=2.9, N=32) in liver cancer patients, (Av=3.5, N=34) in esophageal cancer patients, and (Av=3.3, N=174) total cancer patients. Figure 5G shows the distribution of total CTCs count in blood samples of healthy subjects, HRP patients and patients with different types of cancer. The total CTCs count in healthy subjects and HRP patients was lower than that in patients with various cancers. CTCs in healthy people are mainly distributed in 0-2, CTCs in HRP patients are mainly distributed in 1-3, and CTCs in cancer patients are mainly distributed in more than 5. Meanwhile, based on Figure 5H, there was no significant
The count of CTCs in patients with various cancers was statistically different from that in healthy subjects and patients with HRP (P<0.001). Besides, the count of CTCs in patients with HRP was significantly higher than that in healthy subjects. The average CTCs count in each group was described as follows: (Av=0.9, N=25) in healthy subjects, (Av=2.4, N=32) in HRP patients, (Av=7.4, N=37) in lung cancer patients, (Av=7.2, N=33) in gastric cancer patients, (Av=7.8, N=38) in colorectal cancer patients, (Av=6.9, N=32) in liver cancer patients, (Av=7.3, N=34) in esophageal cancer patients, and (Av=7.3, N=174) total cancer patients.
Correlation Analysis Between Clinicopathological Parameters of Patients and CTCs Counts

Group t-test or one-way analysis of variance were used to analyze the correlation between the CTCs counts in blood samples of the enrolled 174 patients and the clinicopathological parameters of cancer patients, as shown in Table 1.

According to the analysis, it was found that there was no evident difference in the average count of total CTCs in patients with different age, gender and smoking history (P>0.05), and there was significant difference in the average count of CTCs between patients with and without metastasis (P<0.05). Among them, EpCAM-LMB CTCs in patients without metastasis were significantly higher, and Vi-LMB CTCs in patients with distant metastases were significantly higher, and the differences were statistically significant (P<0.001) (Figures 6A, B). The average count of total CTCs was also correlated with tumor stage, which was higher in patients with stage III+IV than those with stage I+II (P<0.05). The count of CTCs in healthy subjects and patients with HRP was significantly lower than that in cancer patients, and there was no significant difference among different cancer patients (Figure 6C).

Furthermore, of the enrolled 174 cancer patients, 86 cancer patients were followed up by telephone. Kaplan-Meier survival analysis was performed on the patients, and the results are shown in Figure 6D. The survival rate showed a decreased trend with the increase of time, which was significantly lower in CTCs>7.3 than that of CTCs<7.3. The mean survival time of CTCs>7.3 and CTCs<7.3 was 8.21 months and 15.54 months, respectively,

### TABLE 1 | Correlation between CTCs count and clinicopathological parameters of patients.

| Clinicopathological parameters | n  | CTCs (x+s) | P    |
|-------------------------------|----|------------|------|
| Age (years)                   |    |            | 0.503|
| ≤60                           | 55 | 6.2 ± 0.33 |      |
| >60                           | 119| 5.9 ± 0.21 |      |
| Gender                        |    |            | 0.153|
| Male                          | 102| 6.3 ± 0.23 |      |
| Female                        | 72 | 5.7 ± 0.29 |      |
| Smoking history               |    |            | 0.718|
| With                          | 77 | 5.9 ± 0.27 |      |
| Without                       | 97 | 6.1 ± 0.24 |      |
| Distant metastasis            |    |            | 0.032|
| With                          | 48 | 8.9 ± 0.30 |      |
| Without                       | 126| 6.7 ± 0.10 |      |
| Tumor stage                   |    |            | <0.041|
| I+II                          | 118| 6.7 ± 0.11 |      |
| III+IV                        | 56 | 8.7 ± 0.28 |      |

FIGURE 6 | Clinical data of cancer patients: (A) Distribution of Ep-LMB CTCs and Vi-LMB CTCs in blood samples of no metastasis and distant metastasis patients; (B) Comparison of average count of Ep-LMB CTCs and Vi-LMB CTCs in blood samples of no metastasis and distant metastasis patients; (C) Kruskal-Wallis test results between healthy subjects, HRP patients, and cancer patients; (D) Survival curve of HRP patients with cancer and those with cancer alone. ***P < 0.001.
which was obviously lower in the former patients when compared with that of the latter patients (P=0.047), this indicates that the survival rate of cancer patients is related to the number of CTCs.

DISCUSSION

Studies have shown that CTCs can serve as a new diagnostic tool, providing information for tumor staging, prognosis (fewer CTCs count indicates longer survival) and evaluation of efficacy in an earlier stage. As a non-invasive method, CTCs count can also provide reference for the biological characteristics of primary and metastatic tumors. CTCs has been found in prostate cancer, colorectal cancer, breast cancer, lung cancer, ovarian cancer, liver cancer, bladder cancer and other solid tumors, which is becoming an independent predictor of tumor prognosis and response to treatment (26, 27). In terms of breast cancer, the count of CTCs (taking ≥5 CTCs/7.5 ml peripheral blood as the threshold) has been proved to be an independent prognostic indicator, which can well predict the progression-free survival (PFS) and overall survival (OS) of patients with metastatic breast cancer. For colorectal cancer patients receiving first-line treatment, the change of CTCs count before and after treatment can be regarded as a predictor of PFS and OS (28). Furthermore, for patients with advanced gastric and esophageal adenocarcinoma receiving first-line chemotherapy, Scalfani et al. (29) documented that patients with ≥2 CTCs in peripheral blood had poor response to chemotherapy and shorter survival time. Besides, the detection of CTCs has been proved to have the advantages of timeliness and higher accuracy compared with traditional imaging (30). However, the detection of CTC depends on the sensitivity of enrichment technology. The only approved CTC detection method is the CellSearch system, which uses EpCAM coated magnetic beads to enrich CTC and anti-CK antibodies for recognition, but the positive rate of CTC detected by this method is 71.1% (31) because it produces negative results for CTC with EMT. Therefore, we add a marker (vimentin) that can recognize mesenchymal CTC, which solves the defects of CellSearch system. The aforementioned studies support that CTCs is an independent predictor of tumor patients’ prognosis and response to treatment. It is worth studying whether CTCs is related to the knock-on effect caused by other diseases. Prior studies were carried out generally in the detection of CTCs in cancer patients. Whether there is CTCs in the blood of normal people and other patients is an issue that has not been valued in the past. Only a few reports have reported the presence of CTCs in healthy subjects and patients with other diseases. For example, Yue Yu et al. (31) detected that the median of CTCs in blood of healthy subjects was 5.71 [4.03-7.38], which was 6.74 [4.64-8.27] and 10.82 [18.21-15.84] in patients with benign diseases and non-small cell lung tumors, respectively. In a study carried out by Fuming Qi et al. (32) the next year, CTCs were detected by PCR in serum samples of 64 patients with bladder cancer and 20 healthy volunteers by using folate receptor

\[ \alpha \text{ as tumor marker.} \]

It was found that the median of CTCs was 26.5 Cu/3mL in the serum of bladder cancer patients and 14.0 Cu/3mL in the control group. In addition, Fei Zhou et al. (33) reported in 2015 that the CTCs of NSCLC patients was 12.41 ± 9.02/3mL, significantly higher than that of benign lung disease patients (6.95 ± 5.45/3mL, p<0.001) and healthy donors (5.95 ± 4.57/3mL, p<0.001).

The above reports suggest that CTCs can be detected in blood of healthy subjects and patients with other diseases. In addition, a recent report on RA revealed that the death rate of rheumatoid arthritis patients due to infection and respiratory diseases is decreasing in recent decades, while the incidence of malignant tumors is increasing (34). A recent study shows that both males and females with rheumatoid arthritis have an increased risk of malignancy (35). As evidenced by the above description, it can be found that CTCs exist in the blood of both cancer patients and non-cancer patients. Simultaneously, inflammation may also be a potential factor for tumor development (36, 37). Accordingly, the present study compared the differences of CTCs among healthy subjects, patients with HRP and cancer patients. It was detected that the CTCs count was (Av=0.9) in healthy subjects, (Av=2.3) in HRP patients and (Av=7.3, N=174) total cancer patients. The count of CTCs in healthy subjects was significantly lower than that in HRP patients and cancer patients, yet without the detection of statistical difference among patients with various cancers.

To sum up, the study confirmed that CTCs can achieve early tumor detection and auxiliary diagnosis, and its number is related to the occurrence and development of tumors, and CTCs can be detected in HRP and sub-health population. As a liquid biopsy technique, it has important clinical application value and will play a huge role in the field of early tumor detection and auxiliary diagnosis.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by The Ethics Committee of Zhabei Central Hospital of Shanghai (ZBLL20180823). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

CYH drafted and wrote the manuscript, SD and CJH revised and reviewed the work, FP, XDL and HJZ collected and analyzed the data, JZ and PS was in charge of the methodology and
REFERENCES

1. Liu X, Li C, Li J, Yu T, Zhou G, Cheng J, et al. Detection of CTCs in Portal Vein Associated With Intrahepatic Metastases and Prognosis in Patients With Advanced Pancreatic Cancer. J Cancer (2018) 9(11):2038–45. doi: 10.7150/jca.23989

2. Sun J, Wang Y, Kai MA, Jianping YU, Hongtao LI, Han X, et al. Research Progress in the Detection Technology of Circulating Tumor Cells and Its Application in Tumor Invasion and Metastasis. Med Recapitulate (2018) 23: R73–37.

3. Kai-Li Z, Xiao-Mei G, Lun-Xiu Q. Fudan University. The Biological Characteristics and Significance of Circulating Tumor Cells in Patients With Solid Malignancies. Fudan Univ J Med Enges (2016) 1:94–8.

4. Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann R. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers (2019) 11(11):1659. doi: 10.3390/cancers11111659

5. Kit OI, Kolesnikov VE, Tolmakh RE, Novikova IA, Demidova AA. Circulating Tumor Cells as a Potential Biomarker in Diagnosis of Lung Cancer: A Systematic Review and Meta-Analysis. Clin Respir J (2018) 12(2):639–45. doi: 10.1111/ crrj.12573

6. Lee MW, Kim GH, Park SJ. Clinical Application of Circulating Tumor Cells in Gastric Cancer. Gut Liver (2019) 13(4):394–401. doi: 10.5009/gnl18484

7. Po JW, A. Possible Contribution of Chronic Inflammation in the Induction of Cancer in Rheumatic Diseases. Clin Exp Rheumatol (2014) 32(6):839–47.

8. Huang H, Shi Y, Huang J, Wang X, Zhang R, Chen X. Circulating Tumor Cells as a Potential Biomarker in Diagnosis of Lung Cancer: A Systematic Review and Meta-Analysis. Jpn J Clin Oncol (2018) 48(9):1512–20. doi: 10.1111/ jocn.13600

9. Yue Y, Chen Z, Dong J, Peng W, He J. Folate Receptor-Positive Circulating Tumor Cells in Esophageal Cancer. J Gastrointest Surg (2017) 21:1112–20. doi: 10.1007/s11605-017-3410-5

10. Kuvendijska J, Brom B, Martini V, Lang S, Pitman M, Hoepner J, et al. Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment. Cancers (2019) 11(3):397. doi: 10.3390/cancers11030397

11. Po JW, Allah R, David L, Anna DF, Michelle H, Harnett PR, et al. Improved Ovarian Cancer EMT-CTC Isolation by Immuno-Magnetizing of Epithelial EpCAM and Mesenchymal N-Cadherin. J Circulating Biomarkers (2018) 7:18495441878261. doi: 10.1177/184954418782617

12. Hyun KA, Goo KB, Han H, Sohn J, Kim YS. Epithelial-to-Mesenchymal Transition Leads to Loss of EpCAM and Different Physical Properties in Circulating Tumor Cells From Metastatic Breast Cancer. Oncotarget (2016) 7(17):24677–87. doi: 10.18632/oncotarget.8250

13. Lecharpentier A, Vieil P, Perez-Moreno P, Planchar D, Sonia JC, Farace F. Detection of Circulating Tumor Cells With a Hybrid (Epithelial/Mesenchymal) Phenotype in Patients With Metastatic Non-Small Cell Lung Cancer. Br J Cancer (2011) 105:1338–41. doi: 10.1038/bjc.2011.405

14. Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, et al. Classification of Circulating Tumor Cells by Epithelial-Mesenchymal Transition Markers. PLoS One (2015) 10:e0123976. doi: 10.1371/journal.pone.0123976

15. Bhardwaj M, Sen S, Chosdol K, Bakhshi S, Pushker N, Sharma A, et al. Vimentin Overexpression as a Novel Poor Prognostic Biomarker in Eyelid Sebaceous Gland Carcinoma. Br J Ophthalmol (2019) 104(6):879–84. doi: 10.1136/bjo-2018-312835

16. Sharma S, Zhuang R, Long M, Pavlovic M, Kang Y, Ilyas A, et al. Circulating Tumor Cell Isolation, Culture, and Downstream Molecular Analysis. Biotechnol Adv (2018) 36(4):1063–78. doi: 10.1016/j.biotechadv.2018.03.007

17. Zhao Y, Xu D, Tan W. Aptamer-Functionalized Nano/Micro-Materials for Clinical Diagnosis: Isolation, Release and Bioanalysis of Circulating Tumor Cells. Int J Biol (2017) 9(3):188–205. doi: 10.1039/C6IB0239K

18. Li Y, Wu S, Bai F. Molecular Characterization of Circulating Tumor Cells: From Bench to Bedside. Semin Cell Dev Biol (2018) 75:88–97. doi: 10.1016/j.semcdb.2017.09.013

19. Rawal S, Yang YP, Cote R, Agarwal A. Identification and Quantitation of Circulating Tumor Cells. Annu Rev Anal Chem (2017) 10(1):321–43. doi: 10.1146/annurev-anchem-061516-045405

20. Hwang WL, Pleskow HM, Miyamoto DT. Molecular Analysis of Circulating Tumor Cells: Biomarkers Beyond Enumeration. Adv Drug Deliv Rev (2018) 125:122–31. doi: 10.1016/j.addr.2018.01.003

21. Shen Z, Wu A, Chen X. Current Detection Technologies for Circulating Tumor Cells. Chemical Soc Rev (2017) 46(8):2038–56. doi: 10.1039/ C6CS00853H

22. Masuda T, Hayashi N, Iguchi T, Ito S, Eguchi H, Mimori K, et al. Clinical and Biological Significance of Circulating Tumor Cells in Cancer. Mol Oncol (2016) 10(1):408–17. doi: 10.1016/j.molonc.2015.10.002

23. Algizawy SM, Essa HH, El-Gezawy E, Omar NN, Sayed DM. Circulating Tumor Cells as an Early Predictive Marker of Disease Progression in Metastatic Breast Cancer Patients. Ann Surg Oncol (2016) 23(7):232. doi: 10.1093/annonc/mdw35.11

24. Curza C, Pop VV, Buiga R, Daniel S, Samasca G. Circulating Tumor Cells in Clinical Research and Monitoring Patients With Colorectal Cancer. Oncotarget (2018) 9(36):24583–61. doi: 10.18632/oncotarget.25337

25. Therl Y, Meddis A, Cabel I, Prouclon C, Latouche A, Pierga J-Y, et al. Circulating Tumor Cells in Early Breast Cancer. INCI Cancer Spectr (2019) 3(2):pk1026. doi: 10.1093/inncjsc/pkt1026.

26. Zhang D, Zhao L, Zhou P, Ma H, Huang F, Jin M, et al. Circulating Tumor Microemboli (CTM) and Vimentin+ Circulating Tumor Cells (Ctcs) Detected by a Size-Based Platform Predict Worse Prognosis in Advanced Colorectal Cancer Patients During Chemotherapy. Cancer Cell Int (2017) 17: 6. doi: 10.1186/s12935-016-0373-7

27. Scalfani F, Smyth E, Cunningham D, Chau L, Turner A, Watkins D. A Pilot Study Assessing the Incidence and Clinical Significance of Circulating Tumor Cells in Esophageagastroscopic Cancers. Clin Colorectal Cancer (2014) 13(2):94–9. doi: 10.1016/j.ccc.2013.11.003

28. Shao-hong L, Xincheng L, Ruming L, Xu J, Ning J, Wu G, et al. Research Progress of Circulating Tumor Cells Detection in Malignant Solid Tumors. Chin J Operative Proc Gen Surg (Electronic Edition) (2016) 5:638–40.

29. Hillig T, Horn P, Nygaard AB, Haugaard AS, Sølteroms G. In Vitro Detection of Circulating Tumor Cells Compared by the CytoTrack and CellSearch Methods. Tumour Biol (2015) 36:6597–601. doi: 10.1007/s13277-015-3105-x

30. Lu X, Tan S, Wu M, Ju H, Li P. Evaluation of a New Magnetic Bead as an Integrated Platform for Systematic CTC Recognition, Capture and Clinical Analysis. Colloids Surfaces B: Biointerfaces (2021) 199:111542. doi: 10.1016/j.colsurf.b.2021.11542

31. Yue Y, Chen Z, Dong J, Peng W, He J. Folate Receptor-Positive Circulating Tumor Cells as a Novel Diagnostic Biomarker in Non-Small Cell Lung Cancer. Trans Oncol (2013) 6(6):697–702. doi: 10.1593/do.13535

32. Qi F, Liu Y, Zhao R, Zou X, Zhang L, Li J, et al. Quantitation of Rare Circulating Tumor Cells by Folate Receptor α Ligand-Targeted PCR in Bladder Transitional Cell Carcinoma and Its Potential Diagnostic Significance. Tumour Biol (2014) 35(7):2177–23. doi: 10.1007/s13277-014-1894-0

FUNDING

This work was supported by The Jing’an District General Project of Shanghai (2018MS07).
35. Chen X, Zhou F, Li X, Yang G, Zhang L, Ren S, et al. Folate Receptor-Positive Circulating Tumor Cell Detected by LT-PCR Based Method as a Diagnostic Biomarker for Non-Small Cell Lung Cancer. J Clin Oncol (2015) 33 (15_suppl):11032–2. doi: 10.1200/jco.2015.33.15_suppl.11032

36. Lee H. The Risk of Malignancy in Korean Patients With Rheumatoid Arthritis. Yonsei Med J (2019) 60(2):223–9. doi: 10.3349/ymj.2019.60.2.223

37. Francescone R, Hou V. Microbiome. Inflammation and Cancer. Cancer J (Sudbury, Mass.) (2014) 20(3):181–9. doi: 10.1097/PPO.0000000000000048

Conflict of Interest: JZ, XL, XW and PS were employed by Huzhou Lieyuan Medical Laboratory Company Ltd.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Huang, Ding, Huang, Pan, Liu, Zhang, Zhou, Liang, Wang and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.